Understanding Rebound High Blood Sugar in Kids Using Automated Insulin Pumps

Rebound hyperglycemia (RH) is when blood sugar swings sharply upward following a low blood sugar episode. In this study, researchers defined it as blood sugar reaching above 10.0 mmol/L (180 mg/dL) within 2 hours after a hypoglycemic event (blood sugar below 3.9 mmol/L or 70 mg/dL).

For people using automated insulin delivery systems—devices that automatically adjust insulin dosing based on continuous glucose monitor readings—understanding this pattern matters because it affects overall blood sugar control and time spent in the target glucose range.

Researchers analyzed continuous glucose monitor data from 190 children and adolescents (average age 11 years) using two types of automated insulin delivery systems. On average, these young people experienced about 9 low blood sugar events per week.

The key finding: approximately 41% of these low blood sugar events were followed by rebound hyperglycemia. This means rebound highs are a common occurrence, not a rare event, for many children and adolescents relying on these systems.

The study measured not just how often rebound highs occurred, but also how severe they were—essentially how high the blood sugar climbed and how long it stayed elevated. Greater severity of rebound hyperglycemia was linked to lower time-in-range (the percentage of time blood sugar stays in the target zone) and higher glycemic variability (larger ups and downs in blood sugar throughout the day).

In other words, young people who experienced more severe rebound highs tended to have worse overall glucose outcomes. This suggests that preventing or minimizing these rebound events could help improve overall diabetes control.

The study compared two main types of automated insulin delivery systems: the CIQ system and the 780G system. While the frequency of rebound hyperglycemia events was similar between the two systems, there was a difference in severity.

Young people using the 780G system experienced lower severity rebound events compared to CIQ users. This suggests that the system itself may influence how pronounced the blood sugar swing is after a low, though both systems still experienced rebound hyperglycemia regularly.

The researchers concluded that rebound hyperglycemia is common and linked to worse glucose outcomes. They point to an important opportunity: optimizing how low blood sugar episodes are treated may reduce rebound hyperglycemia, regardless of which automated insulin delivery system a person uses.

This means that how young people and their families respond to and treat low blood sugar—whether through carbohydrate intake, timing, or other approaches—may be an area where they have more control than previously thought. Working with your healthcare team to develop a personalized hypoglycemia treatment plan could be worth exploring.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.